Synthesis, structure and biological properties of Z-17α-(2-iodovinyl)-11β-chloromethyl estradiol-17β (Z-CMIV), a high affinity ligand for the characterization of estrogen receptor-positive tumors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 59, Issue 1, 1996, Pages 103-117

  Quivy, Jacques ^a   Leclercq, Guy ^a   Deblaton, Marcel ^b   Henrot, Pierre ^b   Velings, Nicolas ^b   Norberg, Bernadette ^c   Evrard, Guy ^c   Zeicher, Marc ^d  

^a JULES BORDET INSTITUTE   (Belgium)

^b National Institute for Radioelements   (Belgium)

^c UNIVERSITY OF NAMUR   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA CHLOROMETHYLESTRADIOL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; IODINE 125; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ESTROGEN ACTIVITY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; NONHUMAN; PROTEIN DOMAIN; RAT; REACTION ANALYSIS; RECEPTOR DENSITY; STEREOCHEMISTRY; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS; UTERUS GROWTH; X RAY CRYSTALLOGRAPHY;

ADENOCARCINOMA; ANIMALS; BINDING SITES; BREAST NEOPLASMS; CRYSTALLOGRAPHY, X-RAY; CYTOSOL; DRUG DESIGN; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; ORGAN SIZE; PROTEIN BINDING; RATS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; UTERUS;

ANIMALIA;

EID: 0030236586     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00007-6     Document Type: Article

References (54)

1. 1. Mintun M. A., Welch M. J., Siegel B. A., Mathias C. J., Brodack J. W., McGuire A. H. and Katzenellenbogen J. A.: Breast cancer: PET imaging of estrogen receptors. Radiology 31 (1988) 45-48.
2. 2). J. Nud. Med. 31 (1990) 937-938.
3. 125I] iodoestradiol for estrogen receptor containing breast cancer cells. Endocrinology 110 (1982) 2177-2179.
4. 4. De Sombre E. R., Harper P. V., Hughes A., Mease R. C., Gatles S. J., De Jesus O. T. and Schwartz J. L.: Bromine-80 m radiotoxicity and the potential for estrogen receptor-directed therapy with Auger electrons. Cancer Res. 48 (1988) 5805-5809.
5. 5. Zeicher M., Henrot P., Loos M., Strijckmans P. and Quivy J.: Z-11β-chloromethyl-17α-iodovinyl-estradiol, a potential agent for targeted radiotherapy of estrogen receptor positive tumors. Eur. J. Nucl. Med. 16, 7 (1990) 439.
6. 6. Brandes S. J. and Katzenellenbogen J. A.: Fundamental considerations in the design of fluorine-18 labeled progestins and androgens as imaging agents for receptor-positive tumors of the breast and prostate. Nucl. Med. Biol. 15 (1988) 53-67.
7. 7. Leclercq G., De Vleeschouwer N., Legros N. and Heuson, J. C.: In vitro screening of cytotoxic estrogens of potential therapeutic activity. In: Cytotoxic Estrogens in Hormone Receptive Tumors (Edited by J. Raus, H. Martens and G. Leclercq). Academic Press, London, (1980) pp. 165-181.
8. 8. Leclercq G., De Vleeschouwer N. and Heuson J. C.: Guide-lines for the design of new antisteroids and cytotoxic-linked estrogens for the treatment of breast cancer. J. Steroid Biochem. 19 (1983) 75-78.
9. 9. Ratajczak T., Sheppard P. N., Capon R. J. and Hahnel R.: The synthesis and study of some potential affinity labelling reagents for estrogen receptors. Steroids 38 (1981) 537-555.
10. 10. van den Broek A. J., Leemhuis J., de Winter M. S. and Zeelen F. J.: Org 4333, a potent, irreversibly binding estrogen agonist. Pharm. Weekbl. Sci. Ed. 5 (1983) 182-183.
11. 11. Reiner G. A., Katzenellenbogen B. S., Bindal R. D. and Katzenellenbogen J. A.: Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells. Cancer Res. 44 (1984) 2302-2308.
12. 3H]estradiol-17β: A very high affinity, reversible ligand for the estrogen receptor. J. Steroid Biochem. 28 (1987) 361-370.
13. 125I]iodo-11β-methoxy-19-norpregna-1,3,5(10),20-tetraene-3,17β-diol(17α-(iodo-vinyl)estradiol derivatives) as high specific activity potential radiopharmaceuticals. J. Med Chem. 27 (1984) 1287-1291.
14. 125I]iodovinyl-11β-methoxyestradiol as a highly selective radioligand for tissues containing estrogen receptors: concise communication. J. Nucl. Med. 25 (1984) 998-1002.
15. 15. Zeicher M. and Quivy J.: Radiolabeled ligands specific for estrogen and progesterone receptor and their use as diagnostic and radiotherapeutic agents and in determination of the receptors. French Patent FR 8813737 (Oct. 19 1988), Eur. Patent 0,365,421 (1992) U.S. Patent 5,002,753 (1991). Chem. Abstr. 114 (1991) 139123h.
16. 125I]iodo-19-norpregna-1,3,5(10),20-tetraene-3, 17-diol. J. Med. Chem. 31 (1988) 1946-1950.
17. 17. Raynaud J. P., Bouton M. A., Gallet-Bourquin D., Philibert D., Tournemine C. and Azadian-Boulanger G.: Comparative study of estrogen action. Mol. Pharmacol. 9 (1973) 520.
18. 18. Quivy J., Henrot P., Deblaton M., Pirotte R. J. and Zeicher M.: Radioiodinated ligands with high affinity for steroid hormone receptors as potential tools for diagnosis and radiotherapy of receptor positive cancers. 9th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology. Las Palmas, Canary Islands, Spain, May 1989.
19. 19. Baran J. S.: A synthesis of 11β-hydroxyestrone and related 16-and 17-hydroxyestratrien. J. Med. Chem. 10 (1967) 1188-1190.
20. 20. Motherwell S.: PLUTO plotting. University Chemical Laboratory, Cambridge, (1978).
21. 21. Vanderveken, D. J.: Vercauteren, D.P. KEMIT program. Scientific Computer Facilities, Department of Chemistry, Facultés N.-D. de la Paix, Namur, (1992).
22. 22. Rousseau G. C., Quivy J. I., Kirchhoff J. and Bui X. H.: Devis R. Nonsteroidal compounds which bind epididymal androgen-binding protein but not the androgen receptor. Nature 284 (1980) 458-459.
23. 23. Scatchard G.: The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51 (1994) 660-672.
24. 24. Legros N., Leclercq G. and McCague R.: Effect of estrogenic and antioestrogenic triphenylethylene derivatives on progesterone and estrogen receptors levels of MCF-7 cells. Biochem. Pharmacol. 42 (1991) 1837-1841.
25. 25. EORTC Breast Cancer Cooperative Group: Revision of the standard for the assessment of hormone receptors in human breast cancer. Eur. J. Cancer 16 (1980) 1513-1515.
26. 26. De Flines J., Vanderwaard W. F., Mijs W. J. and Szpilfogel S. A.: Microbiological conversion of 19-notestosterone (II) 10-and 11-hydroxylation. J. Royal Neth. Chem. Soc. 82 (1963) 129-138.
27. 27. Neuman W. P,: Tri-n-butyltin hybrid as reagent in organic synthesis. Synthesis (1987) 665-683.
28. 28. Cummins C. H.: Radiolabeled steroidal estrogens in cancer research. Steroids 58 (1993) 245-257.
29. 29. Busetta B. and Hospital M.: Structure cristalline et moléculaire de l'oestradiol hémihydrate. Acta Crust. B28 (1972) 560-567.
30. 30. Courseille C., Busetta B., Precigoux G. and Hospital M.: Structure cristalline et moléculaire du methoxy-11β oestradiol. Acta Cryst. B29 (1973) 2462-2465.
31. 31. Lindstedt A., West N. B. and Brenner R. M.: Analysis of monomeric-dimeric states of the estrogen receptor with monoclonal antiestrophilins. J. Steroid Biochem. 24 (1985) 677-686.
32. 32. Giambiagi N. and Pasqualini J. R.: Interaction of three monoclonal antibodies with the nonactivated and activated forms of estrogen receptor. Endocrinology 126 (1990) 1403-1409.
33. 33. Kral L. G., Doherty L. M. and Brooks S. C.: Quantitative determination of nuclear estrogen receptors by an enzyme immunoassay: applicability and caveats. J. Steroid Biochem 31 (1988) 459-466.
34. 34. Marsigliante S., Puddefoot J. R., Barker S., Gledhill J. and Vinson G. P.: Discrepancies between antibody (EIA) and saturation analysis of estrogen receptor content in breast tumor samples. J. Steroid. Biochem. Molec. Biol. 37 (1990) 643-648.
35. 35. Eckert R. L. and Katzenellenbogen B. S.: Effects of estrogen and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res. 42 (1982) 139-144.
36. 125I]-iodovinyl-11β-ethyl-estradiol. Nucl. Med. Biol. 20 (1993) 351-358.
37. 37. French A. N., Napolitano E., Vanbrocklin H. F., Hanson R. N., Welch M. J. and Katzenellenbogen J. A.: Synthesis, radiolabeling and tissue distribution of 11β-Fluoroalkyl-and 11β-Fluoroalkoxy-substituted estrogens: Target tissue uptake selectivity and defluorination of a homologous series of Fluorine-18-labeled estrogens. Nucl. Med. Biol. 20 (1993) 31-47.
38. 38. Ojasoo T., Raynaud J. P. and Mornon J. P.: Steroid hormone receptors. In: Comprehensive Medicinal Chemistry, (Edited by J. C. Emmett). Pergamon Press, Oxford, Vol. 3 (1990) pp. 1175-1226.
39. 39. Ojasoo T., Delettré J., Mornon J. P., Turpin-VanDycke C. and Raynaud J. P.: Towards the mapping of the progesterone and androgen receptors. J. Steroid Biochem. 27 (1987) 255-269.
40. 125I]iodoethenyl]-androsta-4,6-dien-17β-ol-3-one, an active-site-directed photoaffinity radiolabel for androgen-binding proteins. J. Label. Compounds Radiopharm. 23 (1993) 853-862.
41. 41. Raynaud J. P., Bissery V., Gaboriaud C., Ojasoo T., Teutsch G. and Mornon J. P.: An analysis of the steroid binding domain of receptors and of ligand structure and binding affinity. In The Steroid/Thyroid Hormone Receptor Family and Gene Regulation, Life Sciences, Vol. 4 (Edited by J. Carlstedt-Duke, H. Eriksson and J.Å. Gustafsson). Birkhauser Verlag AG, Basel (1994) pp. 337-366.
42. 42. Ojasoo T, Doré J. C., Mornon J. P. and Raynaud J. P.: Two approaches to structure-activity relationships in the field of sex-steroids and their analogs. In Molecular Structure and Biological Activity of Steroids (Edited by M. Bohl and W. L. Duax). CRC Press, Boca Raton (1992) pp. 157-207.
43. 43. Goldstein R. A., Katzenellenbogen J. A., Luthey-Schulten Z. A., Seielstad D. A. and Wolynes P. G.: Three-dimensional model for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9949-9953.
44. 44. Lewis D. F. V., Parker M. G. and King R. J. B.: Molecular modeling of the human estrogen receptor and ligand interactions based on site-directed mutagenesis amino acid sequence homology. J. Steroid Biochem. Molec. Biol. 52 (1995) 55-65.
45. 45. Bourguet W., Ruff M., Chambon P., Gronemeyer H. and Moras D.: Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-a. Nature 375 (1995) 377-382.
46. 46. Ojasoo T. and Raynaud J. P.: Unique steroid congeners for receptor studies. Cancer Res. 38 (1978) 4186-4198.
47. 47. Verschueren K. H. G., Seljée F., Rozeboom H. J., Kalk K. H. and Dijkstra B. A.: Crystallographic analysis of the catalytic mechanism of haloalkane dehydrogenase. Nature 363 (1993) 693-698.
48. 48. Perutz M. F., Fermi G., Abraham D. J., Poyart C. and Bursaux E.: Hemoglobin as a receptor of drugs and peptides: X-ray studies of the stereochemistry of binding. J. Am. Chem. Soc. 108 (1986) 1064-1078.
49. 49. Napolitano E., Fiaschi R., Carlson K. A. and Katzenellenbogen J. A.: 11β-substituted estradiol derivatives, potential high-affinity carbon-11-labeled probes for the estrogen receptor: a structure-affinity relationship study. J. Med. Chem. 38 (1995) 429-434.
50. 125I]-labelled Z-17α-iodovinyl-11β-chloromethyl-estradiol. Nucl. Med. Biol. 23 (1996) 69-73.
51. 51. Quivy J., Delcorde A., Piccart M., Nogaret J. M., Zeicher M. and Frühling J.: Breast cancer imaging and intracellular radiotherapy potency of a high affinity ER ligand, Z-CMIV. 5th International Congress "Hormones and Cancer", Quebec, Canada, Sept. 16-20 (1995) Abs. 25 p. 81.
52. 52. Piccart M., Muquardt C., Pirotte P., Veenstra S., Grillo F. and Leclercq G.: Comparison between tritiated estradiol and tamoxifen aziridine for measuring estrogen receptors in human breast cancer cytosols. J. Natl. Cancer Inst. 83 (1991) 1553-1559.
53. 53. Wei L. L.: Transcriptional activation of the estrogen receptor. Clin. Chem. 39 (1993) 341-345.
54. 54. Sluyser M.: Role of estrogen receptorvariants in the development of hormone resistance in breast cancer. Clin. Biochem. 25 (1992) 407-414.